Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer

ABSTRACT Objective Human epidermal growth factor receptor 2 (HER2) overexpression occurs in up to 30% of breast cancer cases. Ado-trastuzumab emtansine (T-DM1) is approved to treat residual HER2-positive breast cancer after neoadjuvant therapy. The aim of this study was to determine the quality-ad...

Full description

Bibliographic Details
Main Authors: Marcos Aurélio Fonseca Magalhães Filho, Pedro Nazareth Aguiar Jr., Milena Brachmans Mascarenhas Neves, Gilberto de Lima Lopes Jr., Auro del Giglio
Format: Article
Language:English
Published: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2022-05-01
Series:Einstein (São Paulo)
Subjects:
Cost-benefit analysis
HER2-positive
Breast neoplasms
Ado-trastuzumab emtansine
Neoplasm, residual
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082022000100300&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082022000100300&tlng=en

Similar Items